<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Approach to the patient with elevated serum amylase or lipase</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Approach to the patient with elevated serum amylase or lipase</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Approach to the patient with elevated serum amylase or lipase</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Santhi Swaroop Vege, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Douglas G Adler, MD, FACG, AGAF, FASGE</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Shilpa Grover, MD, MPH, AGAF</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 14, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Serum amylase and lipase are common tests obtained as biochemical markers for acute pancreatitis in patients presenting with abdominal pain. However, the interpretation of these tests can be difficult since several non-pancreatic conditions can present with abnormal serum amylase and lipase levels [<a href="#rid1">1,2</a>]. We recommend estimating lipase levels alone for the diagnosis of acute pancreatitis as it is more sensitive than amylase, lasts longer, and is elevated in conditions like hypertriglyceridemia where amylase may be normal [<a href="#rid3">3,4</a>]. However, amylase levels continue to be frequently ordered concurrently [<a href="#rid5">5</a>]. Once the diagnosis of acute pancreatitis is established, serial estimation of pancreatic enzymes may not add much value to the management of the patient.</p><p>This topic review will present an approach to the patient with an elevated serum amylase or lipase. Elevation of these measures in the context of individual disorders (such as pancreatitis) is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5652.html" rel="external">"Clinical manifestations and diagnosis of acute pancreatitis", section on 'Pancreatic enzymes and products'</a>.)</p><p class="headingAnchor" id="H2813740684"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Elevations in pancreatic enzymes are not specific for acute pancreatitis. Between 11 and 13 percent of patients with non-pancreatic abdominal pain have elevated pancreatic enzymes [<a href="#rid1">1,2</a>]. Up to 24 percent of patients with diabetic ketoacidosis have non-specific elevations of lipase [<a href="#rid6">6</a>]. In a group of asymptomatic HIV-positive patients, 60 percent had an abnormal amylase or lipase measurement on at least one occasion [<a href="#rid7">7</a>].</p><p class="headingAnchor" id="H4232709638"><span class="h1">PATHOPHYSIOLOGY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Amylase </strong>– The main function of amylase is to cleave starch into smaller polysaccharides at the internal 1 to 4 alpha linkage in the process of digestion. The main sources of amylase in humans are the pancreas and salivary glands, but it can be found in other tissues in small quantities [<a href="#rid8">8</a>]. </p><p></p><p class="bulletIndent1">Several isoforms of amylase can be identified by electrophoresis; the most abundant are the S form of salivary origin and the P form derived from the pancreas, which contribute to 60 and 40 percent of the circulating amylase, respectively [<a href="#rid8">8</a>]. The molecular weight of the isoforms is relatively small (about 50,000 Daltons) so they can be filtered by the kidneys [<a href="#rid8">8</a>]. Amylase is cleared by the reticuloendothelial system (75 percent) and the kidneys (25 percent). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lipase </strong>–<strong> </strong>Lipase is mainly synthesized and stored as granules in the pancreatic acinar cells. There are several lipases in the human body, including lingual, pancreatic, lipoprotein, intestinal, gastric, and hepatic lipase. Activity of all the lipases is inhibited by bile acids. The activity of pancreatic lipase depends upon the presence of another enzyme, colipase, which facilitates attachment to triglyceride droplets and prevents bile salts from deactivating pancreatic lipase. One of the commonly used assays for pancreatic lipase takes advantage of this property; bile acids and colipase are added to the assay to inhibit all lipases other than pancreatic lipase, thus providing a specific assay for pancreatic lipase.</p><p></p><p class="bulletIndent1">The main function of the pancreatic lipase is to hydrolyze triglycerides into glycerol and free fatty acids. Like amylase, lipase is a relatively small molecule that can be filtrated by the kidney. Unlike amylase, lipase can be reabsorbed in the renal tubules, which increases its half-life (6.9 to 13.7 hours).</p><p></p><p class="headingAnchor" id="H4"><span class="h1">CAUSES</span></p><p class="headingAnchor" id="H4283973400"><span class="h2">Elevations in amylase and lipase</span><span class="headingEndMark"> — </span>Elevated amylase and lipase may be due to increase in pancreatic or extrapancreatic production or a decrease in clearance (<a class="graphic graphic_table graphicRef63497" href="/z/d/graphic/63497.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef64829" href="/z/d/graphic/64829.html" rel="external">table 2</a>). However, in some cases, pancreatic enzymes can be elevated in the absence of an identifiable disease. Hence, estimation of these enzymes without a valid reason is to be discouraged.</p><p class="headingAnchor" id="H4097951215"><span class="h3">Pancreatic disease</span><span class="headingEndMark"> — </span>Patients with acute pancreatitis typically have an acute threefold elevation of amylase and/or lipase. However, enzyme elevations may not be as significant in patients with acute on chronic pancreatitis and alcoholic pancreatitis. Pancreatic enzymes may be elevated following trauma to the pancreas, post-endoscopic retrograde cholangiopancreatography, or pancreatic ductal obstruction or surgery. (See <a class="local">'Isolated/predominant lipase elevation'</a> below.)</p><p class="headingAnchor" id="H3621092048"><span class="h3">Extrapancreatic disease</span><span class="headingEndMark"> — </span>Amylase and lipase elevation are not specific to the pancreatic disease and may be elevated in patients with other intra- or extra-abdominal conditions or the use of medications (<a class="graphic graphic_table graphicRef63497" href="/z/d/graphic/63497.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef77323" href="/z/d/graphic/77323.html" rel="external">table 3</a> and <a class="graphic graphic_table graphicRef77633" href="/z/d/graphic/77633.html" rel="external">table 4</a> and <a class="graphic graphic_table graphicRef64829" href="/z/d/graphic/64829.html" rel="external">table 2</a>). While most extrapancreatic causes of pancreatic enzyme elevations are not associated with a greater than threefold elevation, lipase greater than three times normal has been reported in patients with renal insufficiency, malignant tumors, cholecystitis, and esophagitis [<a href="#rid9">9</a>].</p><p class="headingAnchor" id="H830875240"><span class="h2">Isolated amylase elevation</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Salivary diseases</strong> – Salivary diseases, including parotitis, associated with alcohol use can result in elevations in serum amylase of salivary origin. The most commonly used amylase assays cannot differentiate between salivary and pancreatic amylase, and measurement of isoenzymes in the serum is not widely available, as it cannot differentiate between acute pancreatitis and other non-pancreatitis abdominal conditions that can cause abdominal pain.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Macroamylasemia</strong> – Serum amylase levels may be elevated in settings in which amylase is bound to other macromolecules like immunoglobulins and polysaccharides, forming complexes known as macroamylase [<a href="#rid10">10</a>]. Several diseases have been described in association with macroamylasemia, including celiac disease, HIV infection, lymphoma, ulcerative colitis, rheumatoid arthritis, and monoclonal gammopathy [<a href="#rid11">11-20</a>]. Because of the size of these complexes, renal excretion is reduced and the amylase level as measured by serologic tests is increased. Such patients typically have chronically elevated serum amylase levels, although the degree of elevation can fluctuate [<a href="#rid11">11</a>]. Macroamylasemia may resolve in patients with celiac disease following a gluten-free diet [<a href="#rid12">12,20</a>]. (See <a class="local">'Patients with isolated amylase elevation'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Idiopathic hyperamylasemia</strong> – Persistent elevations in amylase may be a normal variant (Gullo's syndrome) and in some cases may be familial [<a href="#rid21">21,22</a>]. Patients with Gullo's syndrome may have elevations in one or both pancreatic enzymes. Enzyme levels may fluctuate with elevations more than 3-fold the upper limit of normal and return to normal, without clinical or radiologic evidence of pancreatic disease [<a href="#rid23">23</a>]. We follow these patients for one year with repeat imaging, and only then make the diagnosis if no other etiology is found. </p><p></p><p class="headingAnchor" id="H2273970023"><span class="h2">Isolated/predominant lipase elevation</span><span class="headingEndMark"> — </span>Several conditions may be associated with a predominant elevation in serum lipase and normal or minimal elevations in amylase. Normoamylasemia is reported in 19 to 32 percent of patients with acute pancreatitis [<a href="#rid24">24</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Delayed presentation of acute pancreatitis</strong> – As serum amylase has a shorter half-life as compared with serum lipase, patients with a delayed presentation of acute pancreatitis can appear to have isolated elevations in lipase. Amylase levels typically normalize within 24 hours of an episode of acute pancreatitis whereas lipase levels remain elevated for several days. (See <a class="local">'Pathophysiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute alcoholic pancreatitis</strong> – Patients with acute alcoholic pancreatitis may present with a normal amylase and elevated serum lipase. In a retrospective review of 284 patients with acute pancreatitis, patients with acute alcoholic pancreatitis were more likely to present with minimal (less than three times the upper limit of normal) elevations in the pancreatic enzymes [<a href="#rid25">25</a>]. Normoamylasemia was significantly associated with a number of previous attacks, suggesting that pancreatic parenchyma is no longer able to produce sufficient amounts of enzymes [<a href="#rid26">26</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute on chronic pancreatitis</strong> – Pancreatic tissue in chronic pancreatitis demonstrates a substantial decline in both amylase and lipase activity, with amylase activity showing a greater decrease compared to lipase (91 versus 26 percent) [<a href="#rid27">27</a>]. (See  <a class="medical medical_review" href="/z/d/html/5649.html" rel="external">"Chronic pancreatitis: Clinical manifestations and diagnosis in adults", section on 'Laboratory findings'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypertriglyceridemia-induced pancreatitis</strong> – In patients with hypertriglyceridemia-induced acute pancreatitis, serum amylase levels may be normal. Serum amylase levels are spuriously low due to a circulatory inhibitor of serum amylase which interferes with the assay, but it can be corrected if lactescent plasma is recognized by the laboratory and serial dilution techniques are performed. (See  <a class="medical medical_review" href="/z/d/html/5655.html" rel="external">"Hypertriglyceridemia-induced acute pancreatitis", section on 'Laboratory findings'</a>.)</p><p></p><p class="headingAnchor" id="H3319369484"><span class="h1">INITIAL APPROACH</span><span class="headingEndMark"> — </span>The approach to the patient with abdominal pain and elevated amylase and/or lipase is based on whether the clinical presentation is consistent with acute pancreatitis.</p><p class="headingAnchor" id="H3999744353"><span class="h2">Presentation consistent with acute pancreatitis</span><span class="headingEndMark"> — </span>Acute pancreatitis should be suspected in a patient with acute onset of a persistent, severe, epigastric pain with tenderness on palpation on physical examination. In patients with characteristic abdominal pain and elevation in serum lipase or amylase up to three times or greater than the upper limit of normal, no imaging is required to establish the diagnosis of acute pancreatitis.</p><p>In patients with serum amylase or lipase levels that are less than three times the upper limit of normal, we obtain abdominal imaging with contrast-enhanced abdominal computed tomography (CT) to establish the diagnosis of acute pancreatitis and to exclude other causes of acute abdominal pain. (See  <a class="medical medical_review" href="/z/d/html/5652.html" rel="external">"Clinical manifestations and diagnosis of acute pancreatitis", section on 'Clinical features'</a>.)</p><p class="headingAnchor" id="H2265029834"><span class="h2">Presentation inconsistent with acute pancreatitis</span></p><p class="headingAnchor" id="H1424922503"><span class="h3">Clinical history</span><span class="headingEndMark"> — </span>The clinical history may provide valuable clues as to the possible cause of abdominal pain and/or elevated pancreatic enzymes. Patients with chronic pancreatitis may report intermittent episodes of abdominal pain during acute exacerbations but may also suffer from chronic, persistent pain caused by chronic inflammation and/or complications of the disease, such as pseudocysts or duodenal stenosis [<a href="#rid28">28</a>]. In pancreatic cancer pain, intensity usually progresses steadily. The presence of pronounced constitutional symptoms (eg, persistent fevers, night sweats, weight loss, decreased activity level) may be suggestive of a systemic neoplastic disease (<a class="graphic graphic_table graphicRef63497" href="/z/d/graphic/63497.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef77323" href="/z/d/graphic/77323.html" rel="external">table 3</a>). </p><p>Other important aspects of the history include a recent history of pancreatic instrumentation (endoscopic retrograde cholangiopancreatography), trauma, cardiac surgery, and the presence of an established diagnosis of a systemic disease associated with pancreatic enzyme elevations. Recurrent acute pancreatitis without obvious other causes may lead to the suspicion of pancreas divisum or sphincter of Oddi dysfunction. A thorough medication history should be obtained, with particular attention paid to drugs that are associated with pancreatic enzyme elevations (<a class="graphic graphic_table graphicRef64829" href="/z/d/graphic/64829.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef77633" href="/z/d/graphic/77633.html" rel="external">table 4</a>), alcohol consumption, and a family history of pancreatitis or asymptomatic pancreatic enzyme elevations. This may help to clarify etiology of pancreatic enzyme elevations in the absence of acute pancreatitis.</p><p class="headingAnchor" id="H4294385452"><span class="h3">Laboratory evaluation</span><span class="headingEndMark"> — </span>We obtain the following laboratory studies, which, if not already performed, should be obtained to rule out other causes of acute abdominal pain: </p><p class="bulletIndent1"><span class="glyph">●</span>Complete blood count, electrolytes</p><p class="bulletIndent1"><span class="glyph">●</span>Alanine aminotransferase, aspartate aminotransferase, bilirubin </p><p class="bulletIndent1"><span class="glyph">●</span>Calcium and albumin</p><p class="bulletIndent1"><span class="glyph">●</span>Pregnancy test in all women of childbearing age</p><p></p><p>As an example, jaundice due to obstruction of the common bile duct by the chronically inflamed pancreatic head may be due to chronic pancreatitis or obstruction due to pancreatic cancer. </p><p class="headingAnchor" id="H2963686429"><span class="h3">Abdominal imaging</span><span class="headingEndMark"> — </span>In patients with abdominal pain that is not characteristic for acute pancreatitis, we perform abdominal imaging with a contrast-enhanced abdominal CT scan or magnetic resonance imaging (MRI) and magnetic resonance cholangiopancreatogram (MRCP) to evaluate the pancreas and to exclude other causes of acute abdominal pain and elevated pancreatic enzymes. The imaging modality chosen will depend on suspected etiology and the presence of renal failure. </p><p>In patients with severe contrast allergy or renal failure, we perform an abdominal MRI without gadolinium. The advantages of MRI over CT include a lower risk of nephrotoxicity from gadolinium in patients without underlying renal disease; the ability of MRI to better categorize fluid collections as acute fluid collections, necrosis, abscess, hemorrhage, and pseudocyst; and the greater sensitivity of MRI to detect mild acute pancreatitis compared with CT. In addition, unlike CT, MRCP delineates the pancreatic and bile ducts better, and MRCP is comparable to endoscopic retrograde cholangiopancreatography for the detection of choledocholithiasis. </p><p class="headingAnchor" id="H149567633"><span class="h1">SUBSEQUENT APPROACH</span><span class="headingEndMark"> — </span>Subsequent management in patients with a negative initial evaluation depends on the presence of continued abdominal pain.</p><p class="headingAnchor" id="H3970292628"><span class="h2">Patients with continued abdominal pain</span><span class="headingEndMark"> — </span>Patients with persistent abdominal pain with negative initial imaging should be evaluated for other causes of abdominal pain. Repeating amylase and/or lipase in such patients is not clinically useful. Additional evaluation with endoscopic ultrasound can be helpful in the diagnosis of chronic pancreatitis, and in patients suspected of having an occult pancreatic malignancy. (See  <a class="medical medical_review" href="/z/d/html/6862.html" rel="external">"Evaluation of the adult with abdominal pain"</a>.)</p><p class="headingAnchor" id="H67775360"><span class="h2">Patients with isolated amylase elevation</span><span class="headingEndMark"> — </span>In patients with isolated elevations in amylase, the diagnosis of macroamylasemia can be established by determining the molecular weight of the serum amylase, by immunologic assays, or the amylase-to-creatinine clearance ratio (ACCR) [<a href="#rid29">29</a>]. In patients with macroamylasemia, the ACCR is reduced because of poor filtration of the large macroamylase complexes. A ratio less than 1 percent on a 24-hour collection strongly supports the diagnosis of macroamylasemia (normal 3 to 4 percent) [<a href="#rid30">30</a>]. </p><p class="bulletIndent1">The ratio is measured by the following formula:</p><p></p><div class="formulaContainer"><div class="formula"><p class="bulletIndent2">ACCR = Amylase(urine) x Creatinine(serum) x 100<br/>            ——————————————————————<br/>             Amylase(serum) x Creatinine(urine)</p></div></div><p></p><p>ACCR is increased in the setting of acute pancreatitis but is not more helpful than serum amylase determinations alone [<a href="#rid31">31</a>]. Even moderate renal insufficiency interferes with accuracy of the ACCR. Furthermore, an increase in the ACCR is not specific to acute pancreatitis and can be seen in patients with severe burns or diabetic ketoacidosis [<a href="#rid32">32</a>]. Precipitation of macroamylase with polyethylene glycol, colorimetric measurement of total amylase activity, and immunoinhibition for the determination of pancreatic isoamylase can be used to estimate pancreatic isoamylase [<a href="#rid33">33</a>].</p><p class="headingAnchor" id="H1840731073"><span class="h2">Patients without persistent abdominal pain</span><span class="headingEndMark"> — </span>In patients in whom abdominal pain has resolved, we do not pursue additional evaluation. </p><p class="headingAnchor" id="H2591578887"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/111701.html" rel="external">"Society guideline links: Acute pancreatitis"</a>.)</p><p class="headingAnchor" id="H13"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – Elevations in pancreatic enzymes are not specific for acute pancreatitis. Between 11 and 13 percent of patients admitted to the hospital with non-pancreatic abdominal pain have elevated pancreatic enzymes. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Etiology of elevated amylase and lipase</strong> – Elevated amylase and lipase may be due to increase in pancreatic or extrapancreatic production or a decrease in clearance (<a class="graphic graphic_table graphicRef63497" href="/z/d/graphic/63497.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef64829" href="/z/d/graphic/64829.html" rel="external">table 2</a>). However, in some cases pancreatic enzymes can be elevated in the absence of an identifiable disease. (See <a class="local">'Causes'</a> above.)</p><p></p><p class="bulletIndent1">Patients with acute pancreatitis typically have a threefold elevation of amylase and/or lipase. However, patients with acute on chronic pancreatitis, hypertriglyceridemia-induced pancreatitis, and alcoholic pancreatitis may only have elevations in lipase. Isolated elevations in amylase may be due to salivary disease, and in rare cases, due to macroamylasemia. (See <a class="local">'Isolated amylase elevation'</a> above and <a class="local">'Isolated/predominant lipase elevation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial evaluation guided by the clinical presentation</strong> – The approach to the patient with abdominal pain and elevated amylase and/or lipase is based on whether the clinical presentation is consistent with acute pancreatitis. (See <a class="local">'Initial approach'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Clinical presentation consistent with acute pancreatitis</strong> – In patients with characteristic abdominal pain and elevation in serum lipase or amylase up to three times or greater than the upper limit of normal, no imaging is required to establish the diagnosis of acute pancreatitis. (See <a class="local">'Presentation consistent with acute pancreatitis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Clinical presentation inconsistent with acute pancreatitis</strong> – In patients whose clinical presentation is not consistent with acute pancreatitis, we obtain a detailed clinical history that includes medications, laboratory evaluation, and abdominal imaging to determine the cause of abdominal pain and elevated pancreatic enzymes. (See <a class="local">'Presentation inconsistent with acute pancreatitis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Additional evaluation in selected patients</strong> – Subsequent management in patients with a negative initial evaluation depends on the presence of continued abdominal pain. (See <a class="local">'Subsequent approach'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients without abdominal pain</strong> – In patients in whom abdominal pain has resolved, we do not pursue additional evaluation. (See <a class="local">'Patients without persistent abdominal pain'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients with persistent abdominal pain </strong>–<strong> </strong>Patients with persistent abdominal pain and negative initial imaging should be evaluated for other causes of abdominal pain. Repeating amylase and/or lipase in such patients is not clinically useful. Additional evaluation with endoscopic ultrasound can be helpful in the diagnosis of chronic pancreatitis, and in patients suspected of having an occult pancreatic malignancy. (See <a class="local">'Patients with continued abdominal pain'</a> above.)</p><p></p><p class="headingAnchor" id="H2533137093"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff thank Dr. Daniel Gelrud, MD and Dr. Frank Gress, MD for their contributions as authors to prior versions of this topic review. </p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Chase CW, Barker DE, Russell WL, Burns RP. Serum amylase and lipase in the evaluation of acute abdominal pain. Am Surg 1996; 62:1028.</a></li><li><a class="nounderline abstract_t">Gumaste VV, Roditis N, Mehta D, Dave PB. Serum lipase levels in nonpancreatic abdominal pain versus acute pancreatitis. Am J Gastroenterol 1993; 88:2051.</a></li><li><a class="nounderline abstract_t">Smith RC, Southwell-Keely J, Chesher D. Should serum pancreatic lipase replace serum amylase as a biomarker of acute pancreatitis? ANZ J Surg 2005; 75:399.</a></li><li><a class="nounderline abstract_t">Ismail OZ, Bhayana V. Lipase or amylase for the diagnosis of acute pancreatitis? Clin Biochem 2017; 50:1275.</a></li><li><a class="nounderline abstract_t">Ritter JP, Ghirimoldi FM, Manuel LSM, et al. Cost of Unnecessary Amylase and Lipase Testing at Multiple Academic Health Systems. Am J Clin Pathol 2020; 153:346.</a></li><li><a class="nounderline abstract_t">Yadav D, Nair S, Norkus EP, Pitchumoni CS. Nonspecific hyperamylasemia and hyperlipasemia in diabetic ketoacidosis: incidence and correlation with biochemical abnormalities. Am J Gastroenterol 2000; 95:3123.</a></li><li><a class="nounderline abstract_t">Argiris A, Mathur-Wagh U, Wilets I, Mildvan D. Abnormalities of serum amylase and lipase in HIV-positive patients. Am J Gastroenterol 1999; 94:1248.</a></li><li><a class="nounderline abstract_t">Pieper-Bigelow C, Strocchi A, Levitt MD. Where does serum amylase come from and where does it go? Gastroenterol Clin North Am 1990; 19:793.</a></li><li><a class="nounderline abstract_t">Frank B, Gottlieb K. Amylase normal, lipase elevated: is it pancreatitis? A case series and review of the literature. Am J Gastroenterol 1999; 94:463.</a></li><li><a class="nounderline abstract_t">Berk JE, Kizu H, Wilding P, Searcy RL. Macroamylasemia: a newly recognized cause for elevated serum amylase activity. N Engl J Med 1967; 277:941.</a></li><li><a class="nounderline abstract_t">Sachdeva CK, Bank S, Greenberg R, et al. Fluctuations in serum amylase in patients with macroamylasemia. Am J Gastroenterol 1995; 90:800.</a></li><li><a class="nounderline abstract_t">Deprettere AJ, Eykens A, Van Hoof V. Disappearance of macroamylasemia in a celiac patient after treatment with a gluten-free diet. J Pediatr Gastroenterol Nutr 2001; 33:346.</a></li><li><a class="nounderline abstract_t">Barera G, Bazzigaluppi E, Viscardi M, et al. Macroamylasemia attributable to gluten-related amylase autoantibodies: a case report. Pediatrics 2001; 107:E93.</a></li><li><a class="nounderline abstract_t">Rabsztyn A, Green PH, Berti I, et al. Macroamylasemia in patients with celiac disease. Am J Gastroenterol 2001; 96:1096.</a></li><li><a class="nounderline abstract_t">Eleccion CB, Hathaway AA. Macroamylasemia in HIV infection. Tex Med 1998; 94:77.</a></li><li><a class="nounderline abstract_t">Bonetti G, Serricchio G, Giudici A, et al. Hyperamylasemia due to macroamylasemia in adult gluten enteropathy. Scand J Clin Lab Invest 1997; 57:271.</a></li><li><a class="nounderline abstract_t">Yoshida K, Minegishi Y, Okawa H, et al. Epstein-Barr virus-associated malignant lymphoma with macroamylasemia and monoclonal gammopathy in a patient with Wiskott-Aldrich syndrome. Pediatr Hematol Oncol 1997; 14:85.</a></li><li><a class="nounderline abstract_t">Cutolo M, Sulli A, Barone A, et al. Macroamylasemia: a possible cause of unexplained hyperamylasemia in rheumatoid arthritis. Br J Rheumatol 1995; 34:290.</a></li><li><a class="nounderline abstract_t">Fujimura Y, Nishishita C, Uchida J, Iida M. Macroamylasemia associated with ulcerative colitis. J Mol Med (Berl) 1995; 73:95.</a></li><li><a class="nounderline abstract_t">Van Gossum A, Cremer M. Macroamylasemia disappearance after gluten withdrawal. Dig Dis Sci 1989; 34:964.</a></li><li><a class="nounderline abstract_t">Gullo L. Familial pancreatic hyperenzymemia. Pancreas 2000; 20:158.</a></li><li><a class="nounderline abstract_t">Gullo L. Chronic nonpathological hyperamylasemia of pancreatic origin. Gastroenterology 1996; 110:1905.</a></li><li><a class="nounderline abstract_t">Rosell-Camps A, Martínez-Cepas P, Riera-Llodrá JM, et al. Benign Pancreatic Hyperenzymemia, Also Known as Gullo's Syndrome. Lab Med 2020; 51:423.</a></li><li><a class="nounderline abstract_t">Clavien PA, Robert J, Meyer P, et al. Acute pancreatitis and normoamylasemia. Not an uncommon combination. Ann Surg 1989; 210:614.</a></li><li><a class="nounderline abstract_t">Lankisch PG, Burchard-Reckert S, Lehnick D. Underestimation of acute pancreatitis: patients with only a small increase in amylase/lipase levels can also have or develop severe acute pancreatitis. Gut 1999; 44:542.</a></li><li><a class="nounderline abstract_t">Spechler SJ, Dalton JW, Robbins AH, et al. Prevalence of normal serum amylase levels in patients with acute alcoholic pancreatitis. Dig Dis Sci 1983; 28:865.</a></li><li><a class="nounderline abstract_t">Yadav D, Agarwal N, Pitchumoni CS. A critical evaluation of laboratory tests in acute pancreatitis. Am J Gastroenterol 2002; 97:1309.</a></li><li><a class="nounderline abstract_t">Neoptolemos JP, Kemppainen EA, Mayer JM, et al. Early prediction of severity in acute pancreatitis by urinary trypsinogen activation peptide: a multicentre study. Lancet 2000; 355:1955.</a></li><li><a class="nounderline abstract_t">Levitt MD. Clinical use of amylase clearance and isoamylase measurements. Mayo Clin Proc 1979; 54:428.</a></li><li><a class="nounderline abstract_t">Dreiling DA, Leichtling JJ, Janowitz HD. The amylase-creatinine clearance ratio. Diagnostic parameter or physiologic phenomenon? Am J Gastroenterol 1974; 61:290.</a></li><li><a class="nounderline abstract_t">Johnson SG, Ellis CJ, Levitt MD. Mechanism of increased renal clearnace of amylase/creatinine in acute pancreatitis. N Engl J Med 1976; 295:1214.</a></li><li><a class="nounderline abstract_t">Levine RI, Glauser FL, Berk JE. Enhancement of the amylase-creatinine clearance ratio in disorders other than acute pancreatitis. N Engl J Med 1975; 292:329.</a></li><li><a class="nounderline abstract_t">Ventrucci M, Cipolla A, Middonno M, et al. Macroamylase detection in serum using selective precipitation: a rapid and reliable assay. Ital J Gastroenterol Hepatol 1999; 31:846.</a></li></ol></div><div id="topicVersionRevision">Topic 5643 Version 23.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8955242" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Serum amylase and lipase in the evaluation of acute abdominal pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7504396" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Serum lipase levels in nonpancreatic abdominal pain versus acute pancreatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15943725" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Should serum pancreatic lipase replace serum amylase as a biomarker of acute pancreatitis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28720341" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Lipase or amylase for the diagnosis of acute pancreatitis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31679011" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Cost of Unnecessary Amylase and Lipase Testing at Multiple Academic Health Systems.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11095328" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Nonspecific hyperamylasemia and hyperlipasemia in diabetic ketoacidosis: incidence and correlation with biochemical abnormalities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10235202" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Abnormalities of serum amylase and lipase in HIV-positive patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1702756" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Where does serum amylase come from and where does it go?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10022647" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Amylase normal, lipase elevated: is it pancreatitis? A case series and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4167531" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Macroamylasemia: a newly recognized cause for elevated serum amylase activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7537446" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Fluctuations in serum amylase in patients with macroamylasemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11593136" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Disappearance of macroamylasemia in a celiac patient after treatment with a gluten-free diet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11389291" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Macroamylasemia attributable to gluten-related amylase autoantibodies: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11316153" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Macroamylasemia in patients with celiac disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9854422" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Macroamylasemia in HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9238763" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Hyperamylasemia due to macroamylasemia in adult gluten enteropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9021818" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Epstein-Barr virus-associated malignant lymphoma with macroamylasemia and monoclonal gammopathy in a patient with Wiskott-Aldrich syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7537158" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Macroamylasemia: a possible cause of unexplained hyperamylasemia in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7542995" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Macroamylasemia associated with ulcerative colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2470561" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Macroamylasemia disappearance after gluten withdrawal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10707931" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Familial pancreatic hyperenzymemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8964417" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Chronic nonpathological hyperamylasemia of pancreatic origin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31860089" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Benign Pancreatic Hyperenzymemia, Also Known as Gullo's Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2479346" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Acute pancreatitis and normoamylasemia. Not an uncommon combination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10075962" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Underestimation of acute pancreatitis: patients with only a small increase in amylase/lipase levels can also have or develop severe acute pancreatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6193932" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Prevalence of normal serum amylase levels in patients with acute alcoholic pancreatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12094843" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : A critical evaluation of laboratory tests in acute pancreatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10859041" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Early prediction of severity in acute pancreatitis by urinary trypsinogen activation peptide: a multicentre study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/449415" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Clinical use of amylase clearance and isoamylase measurements.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4831310" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The amylase-creatinine clearance ratio. Diagnostic parameter or physiologic phenomenon?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/980035" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Mechanism of increased renal clearnace of amylase/creatinine in acute pancreatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/804138" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Enhancement of the amylase-creatinine clearance ratio in disorders other than acute pancreatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10669992" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Macroamylase detection in serum using selective precipitation: a rapid and reliable assay.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
